Here, we take a look at Wellagyl by Silab, with David Boudier, Scientific Communication Manager.
WELLAGYL® is the first active ingredient in the industry addressing the “well-aging” concept, a vision of beauty clearly expressed by women determined to enhance their well-being while staying in harmony with their age. It allows skin care brands to offer to end-users the solution to look their age and to feel confident with this.
Obtained from the Bulgarian rose (Rosa damascena), whose benefits mostly target the body’s general well-being, WELLAGYL® activates the well-aging process. It thus allows women with poorly-aging skin to recover the cutaneous characteristics of their age. Women’s skin becomes healthy, hydrated and relaxed once more, revealing their natural, mature beauty. WELLAGYL® must be considered as the roadmap of aging well.
How is your product innovative?
For the first time in the cosmetics industry, SILAB advanced researchers demonstrated, in vitro and in vivo, that the biological and clinical signatures of aged skin could be divided into two groups: a “well-aging” group and a “poorly-aging” group.
More precisely, in vivo studies, gathering consumers in focus groups on the topic of aging well and assessing their responses during these discussions through a robust mathematical analysis, allowed to make the clinical profile of a person aging with a positive or a negative outlook.
This study led to the identification of four cutaneous parameters (hydration, firmness, skin complexion and wrinkles) associated with the well-aging concept which were validated in vivo by biometrological approaches and enabled to pre-select volunteers for the clinical substantiation of WELLAGYL®.
In parallel, SILAB proved by bioinformatics analysis that two transcriptomic signatures are discriminated within aged skin cells in vitro, involving three major biological pathways (proliferation; migration; adhesion); features that were confirmed in reconstructed skin 3D models.)
WELLAGYL® is the first and single natural active ingredient currently on the cosmetic market with such a high scientific relevance on this well-aging concept.
Efficacy and innovation
- At the level of cells, WELLAGYL® enables fibroblasts aging poorly to acquire the phenotype specific to a well-aging state by acting on the biological pathways of proliferation, migration and adhesion.
- At the level of tissues, WELLAGYL® reactivates the metabolism. Tested on SILABSKIN® FT model of reconstructed skin "aging poorly", it significantly improves the thickness of the epidermis, the synthesis of procollagen I and the synthesis of hyaluronic acid, restoring them an “aging well” profile.
- At the level of the individual, tested at 2.5% in an emulsion and twice-daily used during 56 days by a group of volunteers, WELLAGYL® significantly improves the four major skin parameters associated with aging well: hydration (+14%), firmness (+9.4%), complexion radiance (+15.7%) and wrinkles (-16.1%).